Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study
HEPATOLOGY（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要